Therapeutic drug monitoring takes guesswork out of antipsychotic care—spotting nonadherence, guiding dose targets, and defining response thresholds and the “point of futility” in schizophrenia.
|Videos|February 8, 2021
Blended Rules: The Home-Work Environment
Author(s)Julie Smirl, LCPC
How has the transition to work from home placed a burden on the shoulders of parents?
Advertisement
Julie Smirl, LCPC, discusses the difficulties of the home-work environment, and how the veil of the professional setting is thinner than ever.
Dr Smirl is an assistant professor at Bradley University and a counselor at Alliance Counseling Services.
Advertisement
Related to this article
A psychiatric NP shares mentorship lessons, training fixes, and her Psych NP Boot Camp—plus practical tips to close prescriber gaps and improve team-based care.
TRD often mislabels depression; learn why MDD heterogeneity demands tailored treatments and when “difficult-to-treat” fits better.
First US TRD Awareness Day spotlights treatment-resistant depression, urging earlier recognition, stigma-breaking support, and renewed hope for patients and caregivers.
FDA approves monthly subcutaneous olanzapine LAI Weltruza, expanding schizophrenia treatment options and renewing debate on making long-acting injectables routine.
Athletes can feel the relief a substance gives them long before they can see what it costs. A composite case of cannabis use in a track athlete shows how to assess both.
How past “untreatable” labels mislead psychiatry—and why measurement-informed care and difficult-to-treat depression replace today’s treatment-resistant mindset.
There is a question older than medicine, and perhaps older than philosophy, that psychiatry has largely avoided: What makes us human?
Advertisement
Advertisement
Trending on Psychiatric Times
1
Reframing “Treatment-Resistant” as “Difficult-To-Treat”
2
The First Ever Treatment-Resistant Depression Awareness Day
3
Formulations Matter: The Approval of Olanzapine Extended-Release Injectable Suspension for Schizophrenia
4
The New, Impending Adult ADHD Guidelines
5